| Autor: |
Eizenberg, Peter, Booy, Robert, Naser, Nadim, Mason, Glen, Stamboulian, Daniel, Weber, Françoise |
| Zdroj: |
Advances in Therapy; Aug2011, Vol. 28 Issue 8, p640-649, 10p |
| Abstrakt: |
INTRODUCTION: Intanza(R) 9 [mu]g (Sanofi Pasteur SA, Lyon, France), a split virion trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available as a vaccination for adults aged 18 to 59 years old, as of the 2010 southern hemisphere influenza season. METHODS: This study was designed to assess the acceptability of intradermal vaccination with Intanza 9 [mu]g in routine clinical practice by adult vaccinees and their prescribers. Prescribers and healthy adults 18 to 59 years old in Australia and Argentina who had elected to be vaccinated with Intanza 9 [mu]g during the 2010 southern hemisphere influenza season were recruited to complete surveys about their opinions of influenza vaccination and acceptance of the intradermal vaccination. RESULTS: 1402 vaccinees and 30 prescribers in Australia, and 264 vaccinees and 16 prescribers in Argentina responded to surveys. In both countries, 98% of vaccinees were satisfied or very satisfied with Intanza 9 [mu]g. The main reasons for satisfaction were that the injection was considered minimally painful and that the vaccination was quickly administered. Most (95%) vaccinees reported that they would prefer to receive the same vaccination next year. Furthermore, 85% of prescribers were satisfied or very satisfied with the intradermal vaccine. CONCLUSION: Intradermal vaccination for seasonal influenza using Intanza 9 [mu]g is well accepted both by adult vaccinees and prescribers. By providing an additional, well-accepted method, Intanza 9 [mu]g might help increase seasonal influenza vaccination rates in adults. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink